MX2016005614A - Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos. - Google Patents

Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.

Info

Publication number
MX2016005614A
MX2016005614A MX2016005614A MX2016005614A MX2016005614A MX 2016005614 A MX2016005614 A MX 2016005614A MX 2016005614 A MX2016005614 A MX 2016005614A MX 2016005614 A MX2016005614 A MX 2016005614A MX 2016005614 A MX2016005614 A MX 2016005614A
Authority
MX
Mexico
Prior art keywords
therapeutic
cosmetic agents
transdermal delivery
inclusion bodies
agents
Prior art date
Application number
MX2016005614A
Other languages
English (en)
Inventor
Ruiz-Avila Luis
BOSSER ARTAL Ramon
Original Assignee
Spherium Biomed S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spherium Biomed S L filed Critical Spherium Biomed S L
Publication of MX2016005614A publication Critical patent/MX2016005614A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A61K8/022—Powders; Compacted Powders
    • A61K8/0225—Granulated powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se relaciona con métodos, composiciones y dispositivos para el suministro transdérmico de agentes terapéuticos y agentes cosméticos en forma de cuerpos de inclusión, estos cuerpos de inclusión. Estos cuerpos de inclusión pueden suministrar agentes terapéuticos y cosméticos a través de la barrera de la piel y llegar a lugares profundos en la piel. Las composiciones descritas pueden usarse para tratar enfermedades y afecciones de la piel.
MX2016005614A 2013-11-01 2014-10-31 Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos. MX2016005614A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361898698P 2013-11-01 2013-11-01
PCT/IB2014/003004 WO2015063613A2 (en) 2013-11-01 2014-10-31 Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents

Publications (1)

Publication Number Publication Date
MX2016005614A true MX2016005614A (es) 2016-12-09

Family

ID=52474023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005614A MX2016005614A (es) 2013-11-01 2014-10-31 Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.

Country Status (9)

Country Link
US (1) US20160250298A1 (es)
EP (1) EP3062889A2 (es)
JP (1) JP2016535770A (es)
KR (1) KR20160083884A (es)
CN (1) CN105813695A (es)
CA (1) CA2928526A1 (es)
MX (1) MX2016005614A (es)
RU (1) RU2016117275A (es)
WO (1) WO2015063613A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101636846B1 (ko) * 2016-06-08 2016-07-07 (주)넥스젠바이오텍 피부 세포 증식 및 항산화 효과가 증가한 보툴리눔 톡신-인간상피세포성장인자 융합단백질 및 이를 유효성분으로 함유하는 피부 재생 및 주름 개선용 화장료 조성물
DE102017107348B4 (de) 2017-04-05 2019-03-14 Olympus Soft Imaging Solutions Gmbh Verfahren zur zytometrischen Analyse von Zellproben
KR101951283B1 (ko) * 2017-11-13 2019-02-22 양미경 탈모의 예방 또는 치료용, 또는 발모 또는 육모 촉진용 약학 또는 화장료 조성물
US20190369119A1 (en) * 2018-06-04 2019-12-05 Avon Products, Inc. Protein Biomarkers for Identifying and Treating Aging Skin and Skin Conditions

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
LU71110A1 (es) 1974-10-15 1976-11-11
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4421769A (en) 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
JPS633791A (ja) 1986-06-25 1988-01-08 Hitachi Ltd プラスミド組換え体
JPS63202387A (ja) 1987-02-18 1988-08-22 Earth Chem Corp Ltd Ｄｎａ配列、これを含むベクタ−、該ベクタ−を保有する宿主細胞及びポリペプチドの製造法
US5034375A (en) 1988-08-10 1991-07-23 Institute Of Molecular Biology, Inc. Process of wound healing using PDGF and EGF
US5102789A (en) 1989-03-15 1992-04-07 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of epideramal growth factor in pichia pastoris yeast cells
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US5183805A (en) 1990-08-13 1993-02-02 Board Of Regents, The University Of Texas System Bioactive egf peptides for promotion of tissue regeneration and cancer therapy
US5145644A (en) 1990-12-20 1992-09-08 Allergan, Inc. Hydrogen peroxide destroying compositions and methods of making and using same
ES2074879T3 (es) 1991-01-16 1995-09-16 Schering Corp Uso de interleuquina-10 en inmunoterapia adoptiva de cancer.
AU2489992A (en) 1991-08-16 1993-03-16 Chiron Corporation Muteins of epidermal growth factor exhibiting enhanced binding at low ph
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US5665345A (en) 1993-05-24 1997-09-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting viral replication using IL-10
EP0706563B1 (en) 1993-06-29 2004-10-06 Chiron Corporation A truncated keratinocyte growth factor (kgf) having increased biological activity
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
EP0845994A1 (en) 1995-08-09 1998-06-10 Schering Corporation Combined use of interleukin-10 and cyclosporin for immunosuppression therapy
PT1486565E (pt) 1995-10-11 2008-02-28 Novartis Vaccines & Diagnostic Combinação de pdgf, kgf, igf e igfbp para cicatrização de ferimentos
US5994306A (en) 1995-11-22 1999-11-30 Intrabiotics Pharmaceuticals, Inc. Fine-tuned protegrins
WO1997020925A1 (en) 1995-12-08 1997-06-12 Hybridon, Inc. Modified vegf antisense oligonucleotides for treatment of skin disorders
US5837265A (en) 1996-03-08 1998-11-17 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties
WO1997034620A1 (en) 1996-03-18 1997-09-25 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
US5753218A (en) 1996-05-03 1998-05-19 Schering Corporation Method for treating inflammation
KR20000029986A (ko) 1996-08-13 2000-05-25 벤슨 로버트 에이치. 각질세포성장인자-2(케이쥐에프-2또는섬유아세포성장인자-12,에프쥐에프-12)
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
PT1012186E (pt) 1996-12-06 2002-12-31 Amgen Inc Utilizacao de produto(s) da proteina kgf e de produto(s) da proteina glp-2 para a preparacao de um medicamento
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
US7001983B1 (en) 1997-02-20 2006-02-21 Yeda Research And Development Co., Ltd. Antipathogenic synthetic peptides and compositions comprising them
US6309656B1 (en) 1998-11-27 2001-10-30 Peter T. Pugliese Cosmetic and skin protective compositions
ES2160485B1 (es) 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
US7307161B1 (en) 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
US6544504B1 (en) 1999-07-28 2003-04-08 Schering Corporation Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy
JP2001186862A (ja) * 1999-10-19 2001-07-10 Makoto Hiuga 粉末状アウレオバシジウム培養液組成物及びその製造方法並びにその組成物を用いた粉末混合物
US20060014684A1 (en) 2000-03-03 2006-01-19 University Technologies International Inc. Novel uses of EGF
EP1267800A4 (en) 2000-03-31 2004-08-25 Gen Hospital Corp M METHODS FOR MODULATING HAIR GROWTH
EP1324779B1 (en) 2000-09-29 2011-07-20 Schering Corporation Pegylated interleukin-10
PL362397A1 (en) 2001-02-06 2004-11-02 Merck Patent Gmbh Modified keratinocyte growth factor (kgf) with reduced immunogenicity
US6875744B2 (en) 2001-03-28 2005-04-05 Helix Biomedix, Inc. Short bioactive peptides
ES2181592B1 (es) 2001-06-14 2003-11-01 Lipotec Sa Uso de glicoproteina para el tratamiento y re-epitelizacion de heridas
CA2453965C (en) 2001-07-19 2016-01-19 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7265089B2 (en) 2001-08-21 2007-09-04 Chiron Corporation KGF polypeptide compositions
JP2003116912A (ja) * 2001-10-15 2003-04-22 Kao Corp 吸収性物品
US6872401B2 (en) 2002-03-28 2005-03-29 L'oreal Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil
SI21273A (sl) * 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
EP1635860A2 (en) 2003-06-12 2006-03-22 Ludwig Institute For Cancer Research Use of vegf-c or vegf-d in reconstructive surgery
EP1634083A2 (en) 2003-06-17 2006-03-15 VIB vzw Peptide combos and their uses
US20050226839A1 (en) 2003-09-08 2005-10-13 Xueying Huang Pepetide-based body surface reagents for personal care
DK1680507T3 (da) 2003-11-06 2011-10-10 Danisco Us Inc Bakterieekspression af proteaseinhibitorer og varianter deraf
ES2293753B1 (es) 2004-04-28 2009-03-16 Lipotec, S.A. Uso de peptidos xikvav en preparacion de composiciones cosmeticas para mejorar la firmeza de la piel mediante el aumento de la adhesion celular.
ES2261036B1 (es) 2004-10-05 2007-12-16 Lipotec, S.A. Peptidos sinteticos que disminuyen o eliminan las bolsas formadas bajo el contorno inferior de los ojos y su uso en composiciones cosmeticas o dermofarmaceuticas.
KR101227301B1 (ko) 2004-11-02 2013-01-29 디에스엠 아이피 어셋츠 비.브이. 표정을 지을때 생기는 주름 및 노화성 주름에 대한 신규한국소 적용제
ES2259928B1 (es) 2005-04-08 2007-11-01 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica que comprende peptidos derivados de encefalinas para reducir y/o eliminar arrugas faciales.
AU2006259408A1 (en) 2005-06-17 2006-12-28 Genentech, Inc. Use of VEGF for wound healing
US20060293227A1 (en) 2005-06-24 2006-12-28 Bhatnagar Rajendra S Cosmetic compositions and methods using transforming growth factor-beta mimics
US20070099889A1 (en) * 2005-07-08 2007-05-03 Paulette Royt Use of pseudan and pseudan inclusion bodies
TW200732347A (en) 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
US8318659B2 (en) 2005-11-15 2012-11-27 E I Du Pont De Nemours And Company Peptide-based organic sunscreens
WO2007065464A1 (en) 2005-12-09 2007-06-14 Stichting Katholieke Universiteit Epidermal growth factor (egf) derivatives with selectable selectivity for the erb receptor family
SG163525A1 (en) 2005-12-23 2010-08-30 Partnership & Corp Technology Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
US20080027005A1 (en) 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
ES2322882B1 (es) 2006-10-25 2010-04-22 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal.
US9340601B2 (en) 2007-03-01 2016-05-17 The Board Of Trustees Of The Leland Stanford Junior University Splice variants of the EGF receptor
US20080234194A1 (en) 2007-03-20 2008-09-25 Harold Brem Growth factor mediated cosmeceuticals and use thereof to enhance skin quality
US8097581B2 (en) 2007-05-10 2012-01-17 Grant Industries Inc. Anti-wrinkle cosmetic composition
BRPI0705059B1 (pt) 2007-06-28 2016-05-31 Univ Rio De Janeiro hidrolisados de queratina, processo para sua produção e composições cosméticas contendo os mesmos
WO2009037061A2 (de) * 2007-09-13 2009-03-26 Basf Se Verwendung von hydrophobin-polypeptiden als penetrationsverstärker
US20090143295A1 (en) 2007-11-30 2009-06-04 E. I. Du Pont De Nemours And Company Peptide-based antiacne reagents
ES2342754B1 (es) 2008-10-03 2011-05-11 Lipotec, S.A. Peptidos utiles en el tratamiento y/o cuidado de la piel, mucosas, cuero cabelludo y/o cabello y su uso en composiciones cosmeticas o farmaceuticas.
ES2352489B1 (es) 2008-12-30 2012-01-04 CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (Titular al 41%) Cuerpos de inclusión, celulas bacterianas y composiciones que los contienen y sus usos.
MX337830B (es) 2009-04-17 2016-03-16 Lipotec Sa Peptidos utiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosmeticas o farmaceuticas.
EP2251025A1 (en) 2009-05-12 2010-11-17 Universitat Autònoma De Barcelona Use of inclusion bodies as therapeutic agents
US8946166B2 (en) 2009-07-24 2015-02-03 Lipotec, S.A. Peptide-based compounds and compositions which inhibit muscle contraction
US20110305735A1 (en) 2010-06-09 2011-12-15 Lipotec, S.A. Skin antiaging treatment
WO2013130913A1 (en) 2012-02-29 2013-09-06 Ambrx, Inc. Interleukin-10 polypeptide conjugates and their uses
EA201500208A1 (ru) 2012-08-08 2015-07-30 Роше Гликарт Аг Слитые белки, содержащие интерлейкин-10, и их применения

Also Published As

Publication number Publication date
KR20160083884A (ko) 2016-07-12
US20160250298A1 (en) 2016-09-01
EP3062889A2 (en) 2016-09-07
CA2928526A1 (en) 2015-05-07
JP2016535770A (ja) 2016-11-17
CN105813695A (zh) 2016-07-27
RU2016117275A (ru) 2017-12-04
WO2015063613A2 (en) 2015-05-07
WO2015063613A3 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2019010601A (es) Terapia de combinacion para tratar cancer.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
WO2015009726A3 (en) Medical uses of cd38 agonists
MY188139A (en) Sodium channel modulators for the treatment of pain
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
MX363543B (es) Composicion farmaceutica que comprende compuesto de diaminocarboxamida heterociclica como ingrediente activo.
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2016005614A (es) Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
NZ725354A (en) Transdermal formulations of pergolide and uses thereof